If you are a prostate cancer patient or caregiver who has perspectives on darolutamide, CCSN wants your feedback. We are looking to hear primarily from non-metastatic castration-resistant prostate cancer patients and their caregivers. However, if you are a patient outside of this specification and feel you may also benefit from this treatment, we would like to hear from you as well.
Clinical trials help to shape the future of medicine. You are a vital part of the drug approval process. Your experiences will help pave the way for new and improved treatments for other prostate cancer patients. We kindly ask that you share your experiences with us in this survey.
Your voice in the process to find new and improved treatments and cures is what matters most in advancing new standards. You can share your unique perspective and be heard by answering this survey, which will inform the Canadian legislature boards of your personal experiences.
By providing us with your input, you are making a valuable contribution to the future of cancer treatments. CCSN values your time and opinions.
The survey will remain open until August 16th, 2019.